Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (412)	5/21/2003 6:27:14 PM
From: Icebrg	Respond to of 631

Isotechnika - ISA.TO I have joined the Isotechnika camp. This is indeed very interesting. The company had its annual meeting today with a webcasted presentation of their technology and development status. Some key points: - ISA 247 is a cyclosporin analogue with less toxicity and higher potency than the original. - The drug is in clinical development for renal transplantation and psoriasis at present (there were some stunning photos of psoriasis patients before and after). - ISA 247 is an orally available small-molecule drug. - The drug is partnered with Roche, who has agreed to pay milestones of up to 210 mUSD to Isotechnika during the drug's development (Roche is as usual very generous. They want their partners to thrive). - The company appears as somewhat of a Sepracor look-alike. They take other company's drugs and improve them. They have even "snatched" one of Sepracor's own isomers. - This looks to my rather untrained eye as a penalty kick (to use a socker term after today's UEFA Cup final). If they are able to develop this drug without any significant side-effects appearing (like QTc-prolongations etc.), it may well become the standard of care for both psoriasis and in transplantation settings. The normal cyclosporin side-effects, which are bad, appear to already have been accounted for. The company is well worth to visit at isotechnika.com Erik

To: Icebrg who wrote (412)	5/21/2003 8:38:14 PM
From: tom pope	Read Replies (1) \| Respond to of 631

5-aminosalicylate is Asacol, I believe. Very anecdotal - and therefore useless - Asacol in my experience is 1) expensive; and 2) useless. I have what my specialist calls "non-specific" colitis, which I assume means he hasn't the vaguest what's going on. Asacol and one of the sulfa drugs had no effect. What does work is a combination of of pred and lomotil. It does nothing to eliminate the underlying problem, but it stops periodic flare-ups in its tracks. Which is all I really need. OTOH - Alcohol Diphenoxylate may enhance the actions of alcohol,2 resulting in increased drowsiness, dizziness, imbalance, and poor response times. Therefore, people taking diphenoxylate should avoid alcohol, especially when staying alert is necessary. Yep.